Yiping Zhang

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 488 citations

Oncology, Clinical Trials, Chemotherapy-naive Patients +9

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 293 citations

Camrelizumab Plus Carboplatin, Medicine, Advanced Squamous Nsclc +8

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study

Baohui Han, Sergei Tjulandin, Koichi Hagiwara et al. · Lung Cancer · 2017 · 149 citations

Advanced Nsclc, Egfr Mutation Prevalence, Medicine +7

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 147 citations · Full text